"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and ...

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and ...

OAB exhibits distinct pathophysiological differences in men and women, complicating diagnosis due to symptom overlap with BPH in men. Engaging patients in the diagnostic process is crucial for ...

Management of mCSPC involves ADT combined with systemic therapies like docetaxel, abiraterone, enzalutamide, or apalutamide. These combination therapies improve overall survival and progression-free ...

"Honestly, there really isn't another measure of sexual quality of life for females that addresses the specific concerns of the female partners of patients with prostate cancer," says Stacy Loeb, MD, ...

What are the next steps for this research? I think the main question is, how does PSA-directed therapy and metastasis-directed therapy affect recurrent metastasis-free survival and survival outcomes ...

“I think as urologists, we need to become more comfortable with the female pelvic floor,” says Ava Saidian, MD. In this video, Ava Saidian, MD, highlights the importance of preventing pelvic prolapse ...

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and ...

"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD. In this video, Kari Bailey, MD, recaps a key point ...

AI scribe technology at Emory University aids in efficient clinical note-taking, potentially enhancing physician satisfaction and reducing after-hours electronic health record usage. AI algorithms are ...

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy. This condition requires alternative therapeutic strategies or radical ...